Abstract
Xanomeline (LY246708/NNC-11-0232) is a potent and selective muscarinic cholinergic M1 receptor agonist which has been shown to cross the blood brain barrier in animals. Increasing central cholinergic activity may provide a rational approach to therapy of Alzheimer’s dementia, since physostigmine and other acetyl cholinesterase inhibitors have shown therapeutic promise in such patients. The non-specificity and side-effect profile of this class of drugs is however less than optimal. As the density of post synaptic M1 receptors in the cortex and hippocampus remains largely unchanged in Alzheimer’s patients it is predicted that a cerebrally bioavailable and specific muscarinic agonist will have therapeutic utility without undesirable side effects.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lucas, R.A., Heaton, J., Carter, G.V., Satterwhite, H. (1995). Single and Multiple Dose Safety, Pharmacodynamics and Pharmacokinetics of Xanomeline, a Novel Muscarinic M1 Agonist in Healthy Male Subjects. In: Hanin, I., Yoshida, M., Fisher, A. (eds) Alzheimer’s and Parkinson’s Diseases. Advances in Behavioral Biology, vol 44. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9145-7_68
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9145-7_68
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9147-1
Online ISBN: 978-1-4757-9145-7
eBook Packages: Springer Book Archive